Correspondence | Published:

Natalizumab and PML

Nature Neuroscience volume 8, page 1275 (2005) | Download Citation

Subjects

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Nat. Neurosci. 8, 837 (2005).

  2. 2.

    & N. Engl. J. Med. 353, 414–416 (2005).

  3. 3.

    Nat. Rev. Drug Discov. 4, 510–518 (2005).

  4. 4.

    , , & Cell 85, 997–1008 (1996).

  5. 5.

    , & Mol. Cell. Biol. 23, 9349–9360 (2003).

  6. 6.

    et al. N. Engl. J. Med. 318, 301–305 (1988).

  7. 7.

    & J. Leukoc. Biol. 65, 428–438 (1999).

  8. 8.

    et al. N. Engl. J. Med. 353, 362–368 (2005).

  9. 9.

    , & Nat. Rev. Immunol. 3, 569–581 (2003).

  10. 10.

    Nat. Rev. Drug Discov. 4, 357–358 (2005).

Download references

Author information

Affiliations

  1. Department of Neurosciences, Neuroinflammation Research Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA. ransohr@ccf.org

    • Richard M Ransohoff

Authors

  1. Search for Richard M Ransohoff in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nn1005-1275

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing